Magnesium Sulfate Svp Pharma (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that act as calcium antagonists at voltage‑gated channels. This produces vasodilation, reduces neuronal excitability, and creates a neuromuscular blockade. The resulting effects stabilize cardiac membranes, suppress uterine contractions, and provide anticonvulsant activity, which are essential in the listed clinical situations.

The specific dose and infusion rate are determined by the prescribing clinician based on the indication, patient weight, renal function, and serum magnesium levels. Healthcare professionals follow established protocols and adjust therapy according to therapeutic monitoring and individual patient response.

Magnesium sulfate is classified as a pregnancy category with unknown risk. It is commonly used in obstetric care for eclampsia, where benefits outweigh potential risks. Use during breastfeeding should be considered only if the prescriber determines that the therapeutic advantage justifies exposure to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Magnesium sulfate is the most widely used injectable magnesium salt because of its high solubility and rapid bioavailability. Compared with magnesium gluconate or magnesium chloride, sulfate provides a larger amount of elemental magnesium per milliliter and has a well‑established safety profile for obstetric and cardiac indications.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particulate matter.

Magnesium sulfate is administered by intramuscular or intravenous injection. Intravenous infusion is usually given slowly over 15‑30 minutes for loading doses, followed by a maintenance infusion as directed by the prescriber. Intramuscular injection may be used when intravenous access is not available.

The most critical risks include severe hypotension, respiratory depression, cardiac arrhythmias such as heart block, and hypermagnesemia leading to loss of deep tendon reflexes or neuromuscular paralysis. Continuous monitoring of blood pressure, respiratory status, cardiac rhythm and serum magnesium levels is essential.

Patients with advanced atrioventricular block without a functioning pacemaker, severe renal impairment, myasthenia gravis, or known hypersensitivity to magnesium sulfate should avoid its use. Clinicians must also assess contraindications related to concurrent medications that may potentiate magnesium toxicity.